Stock Events

Stock Events

Galmed Pharmaceuticals 

$0.6160
28
+$0.00+0.65% Monday 20:00

Statistics

Day High
0.6383
Day Low
0.5851
52W High
2.34
52W Low
0.411
Volume
130,858
Avg. Volume
-
Mkt Cap
3.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q2 2024
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Next
-1.94
-1.4
-0.87
-0.33
Expected EPS
-0.39
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-15.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLMD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.25B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap3.34B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap1.68B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap292.07B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes. Aramchol is also being investigated in the Phase IIa ARRIVE Study, which targets HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Beyond Aramchol, the company is developing Amilo-5MER, a synthetic peptide composed of five specific amino acids: methionine, threonine, alanine, aspartic acid, and valine. Galmed has established several strategic collaborations, including: A research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH, merging ASC41 (a THR-beta agonist) with Aramchol (an SCD1 inhibitor). A research and development partnership with MyBiotics Pharma Ltd. to identify specific microbiome profiles linked to how patients respond to Aramchol. A licensing agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in South Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is based in Tel Aviv, Israel.
Show more...
CEO
Mr. Allen Baharaff
Employees
3
Country
Israel
ISIN
IL0011313900

Listings

F
DE
GPH.F
XNAS
US
GLMD
BOATS
BOATS
GLMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Galmed Pharmaceuticals stock price today?▼
The current price of GLMD is $0.62 USD — it has increased by +0.65% in the past 24 hours. Watch Galmed Pharmaceuticals stock price performance more closely on the chart.
What is Galmed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galmed Pharmaceuticals stocks are traded under the ticker GLMD.
Is Galmed Pharmaceuticals stock price growing?▼
GLMD stock has risen by +18.05% compared to the previous week, the month change is a +2.67% rise, over the last year Galmed Pharmaceuticals has showed a -64.29% decrease.
What is Galmed Pharmaceuticals market cap?▼
Today Galmed Pharmaceuticals has the market capitalization of 3.38M
When is the next Galmed Pharmaceuticals earnings date?▼
Galmed Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Galmed Pharmaceuticals earnings last quarter?▼
GLMD earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.54 USD resulting in a +38.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galmed Pharmaceuticals revenue for the last year?▼
Galmed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Galmed Pharmaceuticals net income for the last year?▼
GLMD net income for the last year is -15.03M USD.
How many employees does Galmed Pharmaceuticals have?▼
As of June 16, 2026, the company has 3 employees.
In which sector is Galmed Pharmaceuticals located?▼
Galmed Pharmaceuticals operates in the Health & Wellness sector.
When did Galmed Pharmaceuticals complete a stock split?▼
The last stock split for Galmed Pharmaceuticals was on August 30, 2024 with a ratio of 1:12.
Where is Galmed Pharmaceuticals headquartered?▼
Galmed Pharmaceuticals is headquartered in Ramat Gan, Israel.